Precursor lesions in pancreatic cancer: Morphological and molecular pathology

Pathology

Volumn 43, Issue 3, 2011, Pages 183-200

  Scarlett, Christopher J ^a   Salisbury, Elizabeth L ^b,c,d   Biankin, Andrew V ^a,e   Kench, James ^a,f,g  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b PRINCE OF WALES HOSPITAL   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d UNIVERSITY OF WESTERN SYDNEY   (Australia)

^e BANKSTOWN LIDCOMBE HOSPITAL   (Australia)

^f ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^g UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Cancer; Pancreas; Pathology; Precursor

Indexed keywords

ANIMAL; CARCINOMA IN SITU; COLLOID CARCINOMA; CYSTADENOCARCINOMA; DISEASE COURSE; DISEASE MODEL; GENETICS; HUMAN; MOLECULAR PATHOLOGY; MOUSE; MUTATION; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; PRECANCER; PROGNOSIS; REVIEW;

ADENOCARCINOMA, MUCINOUS; ANIMALS; CARCINOMA IN SITU; CARCINOMA, PANCREATIC DUCTAL; CYSTADENOCARCINOMA, MUCINOUS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HUMANS; MICE; MUTATION; PANCREATIC NEOPLASMS; PATHOLOGY, MOLECULAR; PRECANCEROUS CONDITIONS; PROGNOSIS;

EID: 79960674148     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1097/PAT.0b013e3283445e3a     Document Type: Review

References (174)

1. Jemal A, Siegel R,Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-49.
2. Australian Institute for Health and Welfare (AIHW). Cancer in Australia: an Overview, 2008. Canberra: AIHW, 2008.
3. Biankin AV, Morey AL, Lee C-S, et al. DPC4/Smad4 expression and outcome in pancreatic ductal adenocarcinoma. J Clin Oncol 2002; 20: 4531-42. (Pubitemid 35402956)
4. Ansari A, Burch GE. A correlative study of proven carcinoma of the pancreas in 83 patients. Am J Gastroenterol 1968; 50: 456-75.
5. Cubilla AL, Fitzgerald PJ. Pancreas Cancer I: Duct adenocarcinoma. A clinico-pathologic study of 380 patients. Pathol Annu 1978; 13: 241-89.
6. Vonlaufen A, Phillips PA, Xu Z, et al. Pancreatic stellate cells and pancreatic cancer cells: an unholy alliance. Cancer Res 2008; 68: 7707-10.
7. Sohn TA, Campbell KA, Pitt HA, et al. Quality of life and long-term survival after surgery for chronic pancreatitis. J Gastrointest Surg 2000; 4: 355-64; discussion 64-5.
8. Trede M, Schwall G, Saeger HD. Survival after pancreatoduodenectomy. 118 consecutive resections without an operative mortality. Ann Surg 1990; 211: 447-58. (Pubitemid 20138186)
9. Winter JM, Cameron JL, Campbell KA, et al. 1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience. J Gastrointest Surg 2006; 10: 1199-210; discussion 210-1.
10. Brat DJ, Lillemoe KD, Yeo CJ, Warfield PB, Hruban RH. Progression of pancreatic intraductal neoplasias to infiltrating adenocarcinoma of the pancreas. Am J Surg Pathol 1998; 22: 163-9. (Pubitemid 28113376)
11. Brockie E, Anand A, Albores-Saavedra J. Progression of atypical ductal hyperplasia/carcinoma in situ of the pancreas to invasive carcinoma. Ann Diagn Pathol 1998; 2: 286-92. (Pubitemid 128646567)
12. Castellano-Sanchez AA, Perez MT, Cabello-Inchausti B,Willis IH, Pelaez B, Davila E. Intraductal carcinoma (carcinoma in situ) of the pancreas with microinvasion. Ann Diagn Pathol 1999; 3: 39-47.
13. Cubilla AL, Fitzgerald PJ. Morphological lesions associated with human primary invasive nonendocrine pancreatic cancer. Cancer Res 1976; 36: 2690-8
14. Solcia E, Capella C, Kloppel G, editors. AFIP Atlas of Tumor Pathology: Tumours of the Pancreas. Third series, Fascicle 20. Washington: ARP Press, 1997; 31-144.
15. Sommers SC, Murphy SA, Warren S. Pancreatic duct hyperplasia and cancer. Gastroenterology 1954; 27: 629-40.
16. Hruban RH, Adsay NV, Albores-Saavedra J, et al. Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol 2001; 25: 579-86. (Pubitemid 32423354)
17. Klimstra DS, Longnecker DS. K-ras mutations in pancreatic ductal proliferative lesions. Am J Pathol 1994; 145: 1547-50. (Pubitemid 24378508)
18. Hruban RH, Pitman MB, Klimstra DS, editors. Ductal adenocarcinoma. In: AFIP Atlas of Tumor Pathology: Tumors of the Pancreas. 4th Series, Fascicle 6. Washington: ARP Press, 2007.
19. Hruban RH, Takaori K, Klimstra DS, et al. An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol 2004; 28: 977-87. (Pubitemid 38971421)
20. Albores-Saavedra J,Weimersheimer-Sandoval M, Chable-Montero F, Montante-Montes de Oca D, Hruban RH, Henson DE. The foamy variant of pancreatic intraepithelial neoplasia. Ann Diagn Pathol 2008; 12: 252-9.
21. Albores-Saavedra J, Wu J, Crook T, Amirkhan RH, Jones L, Hruban RH. Intestinal and oncocytic variants of pancreatic intraepithelial neoplasia. A morphological and immunohistochemical study. Ann Diagn Pathol 2005; 9: 69-76. (Pubitemid 40460740)
22. Andea A, Sarkar F, Adsay VN. Clinicopathological correlates of pancreatic intraepithelial neoplasia: a comparative analysis of 82 cases with and 152 cases without pancreatic ductal adenocarcinoma. Mod Pathol 2003; 16: 996-1006. (Pubitemid 37280815)
23. Luttges J, Reinecke-Luthge A, Mollmann B, et al. Duct changes and K-ras mutations in the disease-free pancreas: analysis of type, age relation and spatial distribution. Virchows Arch 1999; 435: 461-8.
24. Kozuka S, Sassa R, Taki T, et al. Relation of pancreatic duct hyperplasia to carcinoma. Cancer 1979; 43: 1418-28. (Pubitemid 9180309)
25. Rebours V, Levy P, Mosnier JF, et al. Pathology analysis reveals that dysplastic pancreatic ductal lesions are frequent in patients with hereditary pancreatitis. Clin Gastroenterol Hepatol 2010; 8: 206-12.
26. Shi C, Klein AP, Goggins M, et al. Increased prevalence of precursor lesions in familial pancreatic cancer patients. Clin Cancer Res 2009; 15: 7737-43.
27. Stelow EB, Adams RB, Moskaluk CA. The prevalence of pancreatic intraepithelial neoplasia in pancreata with uncommon types of primary neoplasms. Am J Surg Pathol 2006; 30: 36-41. (Pubitemid 43740207)
28. Cerny WL, Mangold KA, Scarpelli DG. K-ras mutation is an early event in pancreatic duct carcinogenesis in the Syrian golden hamster. Cancer Res 1992; 52: 4507-13.
29. Hruban RH, Adsay NV, Albores-Saavedra J, et al. Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations. Cancer Res 2006; 66: 95-106. (Pubitemid 43166014)
30. Yachida S, Jones S, Bozic I, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010; 467: 1114-7.
31. Biankin AV, Kench JG, Biankin SA, Dijkman FP, Henshall SM, Sutherland RL. Molecular pathogenesis of precursor Lesions of pancreatic ductal adenocarcinoma. Pathology 2003; 35: 14-24. (Pubitemid 36349941)
32. Biankin AV, Kench JG, Morey AL, et al. Overexpression of p21WAF1/ CIP1 is an early event in the development of pancreatic intraepithelial neoplasia. Cancer Res 2001; 61: 8830-7. (Pubitemid 34013897)
33. College of American Pathologists. Cancer Protocols: Pancreas (Exocrine). Northfield, IL: CAP, 2009.
34. Longnecker DS, Adsay NV, Fernandez-del Castillo C, Hruban RH, Kasugai T, Klimstra DS, et al. Histopathological diagnosis of pancreatic intraepithelial neoplasia and intraductal papillary-mucinous neoplasms: interobserver agreement. Pancreas 2005; 31: 344-9. (Pubitemid 41566883)
35. Sipos B, Frank S, Gress T, Hahn S, Kloppel G. Pancreatic intraepithelial neoplasia revisited and updated. Pancreatology 2009; 9: 45-54.
36. Hisa T, Suda K, Nobukawa B, et al. Distribution of intraductal lesions in small invasive ductal carcinoma of the pancreas. Pancreatology 2007; 7: 341-6. (Pubitemid 47482095)
37. Kloppel G, Lohse T, Bosslet K, Ruckert K. Ductal adenocarcinoma of the head of the pancreas: incidence of tumor involvement beyond the Whipple resection line. Histological and immunocytochemical analysis of 37 total pancreatectomy specimens. Pancreas 1987; 2: 170-5.
38. Malumbres M, Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer 2003; 3: 459-65. (Pubitemid 37328850)
39. Campbell SL, Khosravi-Far R, Rossman KL, Clark GJ, Der CJ. Increasing complexity of Ras signaling. Oncogene 1998; 17: 1395-413. (Pubitemid 28458409)
40. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988; 53: 549-54.
41. Hruban RH, van Mansfeld AD, Offerhaus GJ, et al. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol 1993; 143: 545-54. (Pubitemid 24058210)
42. Rozenblum E, Schutte M, Goggins M, et al. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res 1997; 57: 1731-4. (Pubitemid 27199667)
43. Lohr M, Kloppel G, Maisonneuve P, Lowenfels AB, Luttges J. Frequency of K-ras mutations in pancreatic intraductal neoplasias associated with pancreatic ductal adenocarcinoma and chronic pancreatitis: a meta-analysis. Neoplasia 2005; 7: 17-23. (Pubitemid 40209467)
44. Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, Depinho RA. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 2006; 20: 1218-49. (Pubitemid 43727584)
45. Day JD, Digiuseppe JA, Yeo C, et al. Immunohistochemical evaluation of HER-2/neu expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms. Hum Pathol 1996; 27: 119-24. (Pubitemid 26049464)
46. Moriya T, Kimura W, Semba S, et al. Biological similarities and differences between pancreatic intraepithelial neoplasias and intraductal papillary mucinous neoplasms. Int JGastrointest Cancer 2005; 35: 111-9. (Pubitemid 41272208)
47. Saxby AJ, Nielsen A, Scarlett CJ, et al. Assessment of HER-2 status in pancreatic adenocarcinoma: correlation of immunohistochemistry, quantitative real-time RT-PCR, and FISH with aneuploidy and survival. Am J Surg Pathol 2005; 29: 1125-34. (Pubitemid 41232983)
48. Maitra A, Adsay NV, Argani P, et al. Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray. Mod Pathol 2003; 16: 902-12. (Pubitemid 37152020)
49. Werb Z. ECM and cell surface proteolysis: regulating cellular ecology. Cell 1997; 91: 439-42. (Pubitemid 27508232)
50. Crawford HC, Scoggins CR, Washington MK, Matrisian LM, Leach SD. Matrix metalloproteinase-7 is expressed by pancreatic cancer precursors and regulates acinar-to-ductal metaplasia in exocrine pancreas. J Clin Invest 2002; 109: 1437-44. (Pubitemid 34596169)
51. Segara D, Biankin AV, Kench JG, et al. Expression of HOXB2, a retinoic acid signaling target in pancreatic cancer and pancreatic intraepithelial neoplasia. Clin Cancer Res 2005; 11: 3587-96. (Pubitemid 40627916)
52. van Heek NT, Meeker AK, Kern SE, et al. Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia. Am J Pathol 2002; 161: 1541-7. (Pubitemid 35265514)
53. Ottenhof NA, Milne AN, Morsink FH, et al. Pancreatic intraepithelial neoplasia and pancreatic tumorigenesis: of mice and men. Arch Pathol Lab Med 2009; 133: 375-81.
54. Lal G, Liu L, Hogg D, Lassam NJ, Redston MS, Gallinger S. Patients with both pancreatic adenocarcinoma and melanoma may harbor germline CDKN2A mutations. Genes Chromosomes Cancer 2000; 27: 358-61. (Pubitemid 30127623)
55. Liu L, Dilworth D, Gao L, et al. Mutation of the CDKN2A 5' UTR creates an aberrant initiation codon and predisposes to melanoma. Nat Genet 1999; 21: 128-32. (Pubitemid 29036299)
56. Hustinx SR, Leoni LM, Yeo CJ, et al. Concordant loss of MTAP and p16/ CDKN2A expression in pancreatic intraepithelial neoplasia: evidence of homozygous deletion in a noninvasive precursor lesion. Mod Pathol 2005; 18: 959-63. (Pubitemid 41059957)
57. Goldstein AM, Fraser MC, Struewing JP, et al. Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N Engl J Med 1995; 333: 970-4.
58. Sherr CJ. The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol 2001; 2: 731-7. (Pubitemid 33679835)
59. Biankin AV, Kench JG, Morey AL, et al. Overexpression of p21(WAF1/ CIP1) is an early event in the development of pancreatic intraepithelial neoplasia. Cancer Res 2001; 61: 8830-7. (Pubitemid 34013897)
60. Maruyama H, Kleeff J, Wildi S, et al. Id-1 and Id-2 are overexpressed in pancreatic cancer and in dysplastic lesions in chronic pancreatitis. Am J Pathol 1999; 155: 815-22. (Pubitemid 29426827)
61. Hermeking H, Lengauer C, Polyak K, et al. 14-3-3 sigma is a p53- regulated inhibitor of G2/M progression. Mol Cell 1997; 1: 3-11. (Pubitemid 127376388)
62. Yu J, Zhang L, Hwang PM, Rago C, Kinzler KW, Vogelstein B. Identification and classification of p53-regulated genes. Proc Natl Acad Sci USA 1999; 96: 14517-22. (Pubitemid 30000682)
63. Yeo TP, Hruban RH, Leach SD, et al. Pancreatic cancer. Curr Probl Cancer 2002; 26: 176-275.
64. Boschman CR, Stryker S, Reddy JK, Rao MS. Expression of p53 protein in precursor lesions and adenocarcinoma of human pancreas. Am J Pathol 1994; 145: 1291-5. (Pubitemid 24378483)
65. Hahn SA, Schutte M, Hoque AT, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996; 271: 350-3.
66. Wilentz RE, Iacobuzio-Donahue CA, Argani P, et al. Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res 2000; 60: 2002-6. (Pubitemid 30207663)
67. Biankin AV, Morey AL, Lee CS, et al. DPC4/Smad4 expression and outcome in pancreatic ductal adenocarcinoma. J Clin Oncol 2002; 20: 4531-42. (Pubitemid 35402956)
68. Luttges J, Galehdari H, Brocker V, et al. Allelic loss is often the first hit in the biallelic inactivation of the p53 and DPC4 genes during pancreatic carcinogenesis. Am J Pathol 2001; 158: 1677-83. (Pubitemid 32422932)
69. Wilentz RE, Iacobuzio-Donahue CA, Argani P, et al. Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res 2000; 60: 2002-6. (Pubitemid 30207663)
70. Siegel PM, Massague J. Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer 2003; 3: 807-21.
71. Lohr M, Schmidt C, Ringel J, et al. Transforming growth factor-beta1 induces desmoplasia in an experimental model of human pancreatic carcinoma. Cancer Res 2001; 61: 550-5. (Pubitemid 32128613)
72. Murphy KM, Brune KA, Griffin C, et al. Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. Cancer Res 2002; 62: 3789-93. (Pubitemid 34728862)
73. Goggins M, Hruban RH, Kern SE. BRCA2 is inactivated late in the development of pancreatic intraepithelial neoplasia: evidence and implications. Am J Pathol 2000; 156: 1767-71. (Pubitemid 30646713)
74. Klein WM, Hruban RH, Klein-Szanto AJ, Wilentz RE. Direct correlation between proliferative activity and dysplasia in pancreatic intraepithelial neoplasia (PanIN): additional evidence for a recently proposed model of progression. Mod Pathol 2002; 15: 441-7. (Pubitemid 34326953)
75. Itai Y, Ohhashi K, Nagai H, et al. ''Ductectatic'' mucinous cystadenoma and cystadenocarcinoma of the pancreas. Radiology 1986; 161: 697-700. (Pubitemid 17200420)
76. Ohhashi K, Murakami Y, Takekoshi T. Four cases of ''mucin producing'' cancer of the pancreas on specific findings of the papilla of Vater. Prog Dig Endosc 1982; 20: 348-51.
77. Hruban RH, Pitman MB, Klimstra DS, editors. AFIP Atlas of Tumor Pathology: Tumors of the Pancreas. 4th Series, Fascicle 6. Washington: ARP Press, 2007; 75-110.
78. Milchgrub S, Campuzano M, Casillas J, Albores-Saavedra J. Intraductal carcinoma of the pancreas. Cancer 1992; 69: 651-6.
79. Payan MJ, Xerri L, Moncada K, et al. Villous adenoma of the main pancreatic duct: a potentially malignant tumor? Am J Gastroenterol 1990; 85: 459-63. (Pubitemid 20140626)
80. Rickaert F, Cremer M, Deviere J, et al. Intraductal mucin-hypersecreting neoplasms of the pancreas: a clinicopathological study of eight patients. Gastroenterology 1991; 101: 512-9.
81. Warshaw AL. Mucinous cystic tumors and mucinous ductal ectasia of the pancreas. Gastrointest Endosc 1991; 37: 199-201.
82. Yamada M, Kozuka S, Yamao K, Nakazawa S, Naitoh Y, Tsukamoto Y. Mucin-producing tumor of the pancreas. Cancer 1991; 68: 159-68.
83. Longnecker DS, Hruban RH, Adler G. Intraductal papillary-mucinous neoplasms of the pancreas. Lyon: IARC Press; 2000; 237-40.
84. Sessa F, Solcia E, Capella C, et al. Intraductal papillary-mucinous tumours represent a distinct group of pancreatic neoplasms: an investigation of tumour cell differentiation and K-ras, p53 and c-erbB-2 abnormalities in 26 patients. Virchows Arch 1994; 425: 357-67.
85. Itai Y, Kokubo T, Atomi Y, Kuroda A, Haraguchi Y, Terano A. Mucinhypersecreting carcinoma of the pancreas. Radiology 1987; 165: 51-5.
86. Chari ST, Yadav D, Smyrk TC, et al. Study of recurrence after surgical resection of intraductal papillary mucinous neoplasm of the pancreas. Gastroenterology 2002; 123: 1500-7. (Pubitemid 35231650)
87. Furukawa T, Takahashi T, Kobari M, Matsuno S. The mucus-hypersecreting tumor of the pancreas. Development and extension visualized by three-dimensional computerised mapping. Cancer 1992; 70: 1505-13.
88. Kench JG, Eckstein RP, Smith RC. Intraductal papillary-mucinous neoplasm of the pancreas: a report of five cases with immunohistochemical findings. Pathology 1997; 29: 7-11. (Pubitemid 27135820)
89. Nagai E, Ueki T, Chijiiwa K, Tanaka M, Tsuneyoshi M. Intraductal papillary mucinous neoplasms of the pancreas associated with so-called ''mucinous ductal ectasia''. Histochemical and immunohistochemical analysis of 29 cases. Am J Surg Pathol 1995; 19: 576-89.
90. Yamaguchi K, Tanaka M. Mucin-hypersecreting tumor of the pancreas with mucin extrusion through an enlarged papilla. Am J Gastroenterol 1991; 86: 835-9.
91. Yamaguchi K, Yokohata K, Noshiro H, Chijiiwa K, Tanaka M. Mucinous cystic neoplasm of the pancreas or intraductal papillary-mucinous tumour of the pancreas. Eur J Surg 2000; 166: 141-8. (Pubitemid 30096871)
92. Azar C, Van de Stadt J, Rickaert F, et al. Intraductal papillary mucinous tumours of the pancreas. Clinical and therapeutic issues in 32 patients. Gut 1996; 39: 457-64. (Pubitemid 26338538)
93. Koito K, Namieno T, Ichimura T, et al. Mucin-producing pancreatic tumors: comparison of MR cholangiopancreatography with endoscopic retrograde cholangiopancreatography. Radiology 1998; 208: 231-7.
94. Kitagawa Y, Unger TA, Taylor S, Kozarek RA, Traverso LW. Mucus is a predictor of better prognosis and survival in patients with intraductal papillary mucinous tumor of the pancreas. J Gastrointest Surg 2003; 7: 12-8; discussion 18-9.
95. Sho M, Nakajima Y, Kanehiro H, et al. Pattern of recurrence after resection for intraductal papillary mucinous tumors of the pancreas.World J Surg 1998; 22: 874-8. (Pubitemid 28322087)
96. Adsay NV, Conlon KC, Zee SY, Brennan MF, Klimstra DS. Intraductal papillary-mucinous neoplasms of the pancreas: an analysis of in situ and invasive carcinomas in 28 patients. Cancer 2002; 94: 62-77. (Pubitemid 34049043)
97. Raut CP, Cleary KR, Staerkel GA, et al. Intraductal papillary mucinous neoplasms of the pancreas: effect of invasion and pancreatic margin status on recurrence and survival. Ann Surg Oncol 2006; 13: 582-94.
98. Bosman FT, Carneiro F, Hruban RH, Thiese ND. WHO Classification of Tumours of the Digestive System. 4th ed. Lyon: IARC, 2010; 280.
99. Sohn TA, Yeo CJ, Cameron JL, et al. Intraductal papillary mucinous neoplasms of the pancreas: an updated experience. Ann Surg 2004; 239: 788-97; discussion 97-9.
100. Adsay NV, Merati K, Iacobuzio-Donahue C, Levi E, Basturk O, Sarkar FS. Pathologically and biologically distinct types of epithelium in intraductal papillary mucinous neoplasms: delineation of an ''intestinal'' pathway of carcinogenesis in the pancreas. Am J Surg Pathol 2004; 28: 839-48. (Pubitemid 38856838)
101. Yonezawa S, Horinouchi M, Osako M, et al. Gene expression of gastric type mucin (MUC5AC) in pancreatic tumors: its relationship with the biological behavior of the tumor. Pathol Int 1999; 49: 45-54. (Pubitemid 29421947)
102. Furukawa T, Kloppel G, Adsay NV, et al. Classification of types of intraductal papillary-mucinous neoplasm of the pancreas: a consensus study. Virchows Arch 2005; 447: 794-9. (Pubitemid 41728866)
103. Adsay NV, Adair CF, Heffess CS, Klimstra DS. Intraductal oncocytic papillary neoplasms of the pancreas. Am J Surg Pathol 1996; 20: 980-94. (Pubitemid 26250638)
104. Warshaw AL, Compton CC, Lewandrowski K, Cardenosa G, Mueller PR. Cystic tumors of the pancreas. New clinical, radiologic, and pathologic observations in 67 patients. Ann Surg 1990; 212: 432-43; discussion 444-5.
105. Thompson LD, Becker RC, Przygodzki RM, Adair CF, Heffess CS. Mucinous cystic neoplasm (mucinous cystadenocarcinoma of low-grade malignant potential) of the pancreas: a clinicopathologic study of 130 cases. Am J Surg Pathol 1999; 23: 1-16. (Pubitemid 29025236)
106. Zamboni G, Scarpa A, Bogina G, et al. Mucinous cystic tumors of the pancreas: clinicopathological features, prognosis, and relationship to other mucinous cystic tumors. Am J Surg Pathol 1999; 23: 410-22. (Pubitemid 29160001)
107. Bendix Holme J, Jacobsen NO, Rokkjaer M, Kruse A. Total pancreatectomy in six patients with intraductal papillary mucinous tumour of the pancreas: the treatment of choice. HPB (Oxford) 2001; 3: 257-62.
108. Biankin AV, Kench JG, Biankin SA, et al. Pancreatic intraepithelial neoplasia in association with intraductal papillary mucinous neoplasms of the pancreas: implications for disease progression and recurrence. Am J Surg Pathol 2004; 28: 1184-92. (Pubitemid 39121612)
109. Couvelard A, Sauvanet A, Kianmanesh R, et al. Frozen sectioning of the pancreatic cut surface during resection of intraductal papillary mucinous neoplasms of the pancreas is useful and reliable: a prospective evaluation. Ann Surg 2005; 242: 774-8; discussion 78-80.
110. Gigot JF, Deprez P, Sempoux C, et al. Surgical management of intraductal papillary mucinous tumors of the pancreas: the role of routine frozen section of the surgical margin, intraoperative endoscopic staged biopsies of theWirsung duct, and pancreaticogastric anastomosis. Arch Surg 2001; 136: 1256-62. (Pubitemid 33043512)
111. Paye F, Sauvanet A, Terris B, et al. Intraductal papillary mucinous tumors of the pancreas: pancreatic resections guided by preoperative morphological assessment and intraoperative frozen section examination. Surgery 2000; 127: 536-44. (Pubitemid 30257512)
112. Cuillerier E, Cellier C, Palazzo L, et al. Outcome after surgical resection of intraductal papillary and mucinous tumors of the pancreas. Am J Gastroenterol 2000; 95: 441-5. (Pubitemid 30106173)
113. D'Angelica M, Brennan MF, Suriawinata AA, Klimstra D, Conlon KC. Intraductal papillary mucinous neoplasms of the pancreas: an analysis of clinicopathologic features and outcome. Ann Surg 2004; 239: 400-8. (Pubitemid 38229071)
114. Maire F, Hammel P, Terris B, et al. Prognosis of malignant intraductal papillary mucinous tumours of the pancreas after surgical resection. Comparison with pancreatic ductal adenocarcinoma. Gut 2002; 51: 717-22. (Pubitemid 35216862)
115. Murakami Y, Uemura K, Sudo T, et al. Invasive intraductal papillarymucinous neoplasm of the pancreas: comparison with pancreatic ductal adenocarcinoma. J Surg Oncol 2009; 100: 13-8.
116. Poultsides GA, Reddy S, Cameron JL, et al. Histopathologic basis for the favorable survival after resection of intraductal papillary mucinous neoplasm-associated invasive adenocarcinoma of the pancreas. Ann Surg 2010; 251: 470-6.
117. Shimada K, Sakamoto Y, Sano T, Kosuge T, Hiraoka N. Invasive carcinoma originating in an intraductal papillary mucinous neoplasm of the pancreas: a clinicopathologic comparison with a common type of invasive ductal carcinoma. Pancreas 2006; 32: 281-7.
118. Sohn TA, Yeo CJ, Cameron JL, Iacobuzio-Donahue C, Hruban RH, Lillemoe KD. Intraductal papillary mucinous neoplasms of the pancreas: an increasingly recognised pathologic entity. Ann Surg 2001; 234: 313-22. (Pubitemid 32847068)
119. Woo SM, Ryu JK, Lee SH, et al. Survival and prognosis of invasive intraductal papillary mucinous neoplasms of the pancreas: comparison with pancreatic ductal adenocarcinoma. Pancreas 2008; 36: 50-5.
120. Thosani N, Dasari CS, Bhutani MS, Raimondo M, Guha S. Molecular pathogenesis of intraductal papillary mucinous neoplasms of the pancreas. Pancreas 2010; 39: 1129-33.
121. Fernandez-del Castillo C, Adsay NV. Intraductal papillary mucinous neoplasms of the pancreas. Gastroenterology 2010; 139: 708-13; 13 e1-2.
122. Kitago M, Ueda M, Aiura K, et al. Comparison of K-ras point mutation distributions in intraductal papillary-mucinous tumors and ductal adenocarcinoma of the pancreas. Int J Cancer 2004; 110: 177-82. (Pubitemid 38580387)
123. Vanhaesebroeck B, Alessi DR. The PI3K-PDK1 connection: more than just a road to PKB. Biochem J 2000; 346 (Pt 3): 561-76. (Pubitemid 30171014)
124. Semba S, Moriya T, Kimura W, Yamakawa M. Phosphorylated Akt/PKB controls cell growth and apoptosis in intraductal papillary-mucinous tumor and invasive ductal adenocarcinoma of the pancreas. Pancreas 2003; 26: 250-7. (Pubitemid 36384157)
125. Satoh K, Shimosegawa T, Moriizumi S, Koizumi M, Toyota T. K-ras mutation and p53 protein accumulation in intraductal mucin-hypersecreting neoplasms of the pancreas. Pancreas 1996; 12: 362-8.
126. Caldas C, Hahn SA, da Costa LT, et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS 1) gene in pancreatic cancer. Nat Genet 1994; 8: 27-32. (Pubitemid 24274057)
127. Schutte M, Hruban RH, Geradts J, et al. Abrogation of the Rb/p16 tumorsuppressive pathway in virtually all pancreatic carcinomas. Cancer Res 1997; 57: 3126-30. (Pubitemid 27351723)
128. Biankin AV, Biankin SA, Kench JG, et al. Aberrant p16INK4A and DPC4/ Smad4 expression in intraductal papillary mucinus tumours of the pancreas is associated with invasive ductal adenocarcinoma. Gut 2002; 50: 861-8. (Pubitemid 34539051)
129. Furukawa T, Fujisaki R, Yoshida Y, et al. Distinct progression pathways involving the dysfunction of DUSP6/MKP-3 in pancreatic intraepithelial neoplasia and intraductal papillary-mucinous neoplasms of the pancreas. Mod Pathol 2005; 18: 1034-42. (Pubitemid 41224493)
130. Sato N, Rosty C, Jansen M, et al. STK11/LKB1 Peutz-Jeghers gene inactivation in intraductal papillary-mucinous neoplasms of the pancreas. Am J Pathol 2001; 159: 2017-22. (Pubitemid 33104257)
131. Su GH, Hruban RH, Bansal RK, et al. Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers. Am J Pathol 1999; 154: 1835-40. (Pubitemid 29262866)
132. Kimura M, Furukawa T, Abe T, et al. Identification of two common regions of allelic loss in chromosome arm 12q in human pancreatic cancer. Cancer Res 1998; 58: 2456-60. (Pubitemid 28252709)
133. Hruban RH, Adsay NV. Molecular classification of neoplasms of the pancreas. Hum Pathol 2009; 40: 612-23.
134. Iacobuzio-Donahue CA, Klimstra DS, Adsay NV, et al. Dpc-4 protein is expressed in virtually all human intraductal papillary mucinous neoplasms of the pancreas: comparison with conventional ductal adenocarcinomas. Am J Pathol 2000; 157: 755-61. (Pubitemid 32109368)
135. Inoue H, Furukawa T, Sunamura M, Takeda K, Matsuno S, Horii A. Exclusion of SMAD4 mutation as an early genetic change in human pancreatic ductal tumorigenesis. Genes Chromosomes Cancer 2001; 31: 295-9. (Pubitemid 32521761)
136. Ueki T, Toyota M, Sohn T, et al. Hypermethylation of multiple genes in pancreatic adenocarcinoma. Cancer Res 2000; 60: 1835-9. (Pubitemid 30207640)
137. Compagno J, Oertel JE. Mucinous cystic neoplasms of the pancreas with overt and latent malignancy (cystadenocarcinoma and cystadenoma). A clinicopathologic study of 41 cases. Am J Clin Pathol 1978; 69: 573-80. (Pubitemid 8366915)
138. Wilentz RE, Albores-Saavedra J, Zahurak M, et al. Pathologic examination accurately predicts prognosis in mucinous cystic neoplasms of the pancreas. Am J Surg Pathol 1999; 23: 1320-7. (Pubitemid 29517325)
139. Yamao K, Yanagisawa A, Takahashi K, et al. Clinicopathological features and prognosis of mucinous cystic neoplasm with ovarian-type stroma: a multi-institutional study of the Japan Pancreas Society. Pancreas 2011; 40: 67-71.
140. Zamboni G, Kloppel G, Hruban RH, Longnecker DS, Adler G. Mucinous cystic neoplams of the pancreas. In: Hamilton SR, Aaltonen LA, editors. World Health Organisation Classification of Tumours Pathology and genetics of tumours of the digestive system. Lyon: IARC Press, 2000; 234-6.
141. Hruban RH, Pitman MB, Klimstra D, editors. AFIP Atlas of Tumor Pathology: Tumors of the Pancreas. 4th Series, Fascicle 6. Washington: ARP Press, 2007; 51-74.
142. Fernandez-del Castillo C, Targarona J, Thayer SP, Rattner DW, Brugge WR, Warshaw AL. Incidental pancreatic cysts: clinicopathologic characteristics and comparison with symptomatic patients. Arch Surg 2003; 138: 427-33; discussion 33-4.
143. Luttges J, Feyerabend B, Buchelt T, Pacena M, Kloppel G. The mucin profile of noninvasive and invasive mucinous cystic neoplasms of the pancreas. Am J Surg Pathol 2002; 26: 466-71. (Pubitemid 34280119)
144. Fukushima N, Mukai K, Kanai Y, et al. Intraductal papillary tumors and mucinous cystic tumors of the pancreas: clinicopathologic study of 38 cases. Hum Pathol 1997; 28: 1010-7. (Pubitemid 27388101)
145. Le Borgne J, de Calan L, Partensky C. Cystadenomas and cystadenocarcinomas of the pancreas: a multiinstitutional retrospective study of 398 cases. French Surgical Association. Ann Surg 1999; 230: 152-61. (Pubitemid 30191880)
146. Lane RB Jr, Sangueza OP. Anaplastic carcinoma occurring in association with a mucinous cystic neoplasm of the pancreas. Arch Pathol Lab Med 1997; 121: 533-5. (Pubitemid 27215160)
147. Brandwein SL, Farrell JJ, Centeno BA, Brugge WR. Detection and tumor staging of malignancy in cystic, intraductal, and solid tumors of the pancreas by EUS. Gastrointest Endosc 2001; 53: 722-7. (Pubitemid 33717244)
148. Frossard JL, Amouyal P, Amouyal G, et al. Performance of endosonography- guided fine needle aspiration and biopsy in the diagnosis of pancreatic cystic lesions. Am J Gastroenterol 2003; 98: 1516-24. (Pubitemid 36875343)
149. Layfield LJ, Cramer H. Fine-needle aspiration cytology of intraductal papillary-mucinous tumors: a retrospective analysis. Diagn Cytopathol 2005; 32: 16-20. (Pubitemid 40024068)
150. Maire F, Couvelard A, Hammel P, et al. Intraductal papillary mucinous tumors of the pancreas: the preoperative value of cytologic and histopathologic diagnosis. Gastrointest Endosc 2003; 58: 701-6. (Pubitemid 37370483)
151. Michaels PJ, Brachtel EF, Bounds BC, Brugge WR, Bishop Pitman M. Intraductal papillary mucinous neoplasm of the pancreas: cytologic features predict histologic grade. Cancer 2006; 108: 163-73.
152. Stelow EB, Bardales RH, Stanley MW. Pitfalls in endoscopic ultrasoundguided fine-needle aspiration and how to avoid them. Adv Anat Pathol 2005; 12: 62-73. (Pubitemid 40515794)
153. Stelow EB, Stanley MW, Bardales RH, et al. Intraductal papillarymucinous neoplasm of the pancreas. The findings and limitations of cytologic samples obtained by endoscopic ultrasound-guided fine-needle aspiration. Am J Clin Pathol 2003; 120: 398-404. (Pubitemid 37295111)
154. Recine M, Kaw M, Evans DB, Krishnamurthy S. Fine-needle aspiration cytology of mucinous tumors of the pancreas. Cancer 2004; 102: 92-9. (Pubitemid 38489966)
155. Zhai J, Sarkar R, Ylagan L. Pancreatic mucinous lesions: a retrospective analysis with cytohistological correlation. Diagn Cytopathol 2006; 34: 724-30. (Pubitemid 44663246)
156. Bartsch D, Bastian D, Barth P, et al. K-ras oncogene mutations indicate malignancy in cystic tumors of the pancreas. Ann Surg 1998; 228: 79-86. (Pubitemid 30190319)
157. Gerdes B, Wild A, Wittenberg J, et al. Tumor-suppressing pathways in cystic pancreatic tumors. Pancreas 2003; 26: 42-8. (Pubitemid 36020265)
158. Iacobuzio-Donahue CA, Wilentz RE, Argani P, et al. Dpc4 protein in mucinous cystic neoplasms of the pancreas: frequent loss of expression in invasive carcinomas suggests a role in genetic progression. Am J Surg Pathol 2000; 24: 1544-8.
159. Jimenez RE, Warshaw AL, Z'Graggen K, et al. Sequential accumulation of K-ras mutations and p53 overexpression in the progression of pancreatic mucinous cystic neoplasms to malignancy. Ann Surg 1999; 230: 501-9; discussion 9-11.
160. Kim SG, Wu TT, Lee JH, et al. Comparison of epigenetic and genetic alterations in mucinous cystic neoplasm and serous microcystic adenoma of pancreas. Mod Pathol 2003; 16: 1086-94. (Pubitemid 37414202)
161. Khalid A, McGrath KM, Zahid M, et al. The role of pancreatic cyst fluid molecular analysis in predicting cyst pathology. Clin Gastroenterol Hepatol 2005; 3: 967-73. (Pubitemid 41415743)
162. Finlay CA, Hinds PW, Tan TH, Eliyahu D, Oren M, Levine AJ. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol 1988; 8: 531-9.
163. Flejou JF, Boulange B, Bernades P, Belghiti J, Henin D. p53 protein expression and DNA ploidy in cystic tumors of the pancreas. Pancreas 1996; 13: 247-52. (Pubitemid 26317993)
164. Aguirre AJ, Bardeesy N, Sinha M, et al. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev 2003; 17: 3112-26. (Pubitemid 38040774)
165. Bardeesy N, Aguirre AJ, Chu GC, et al. Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc Natl Acad Sci USA 2006; 103: 5947-52.
166. Hingorani SR, Petricoin EF, Maitra A, et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 2003; 4: 437-50. (Pubitemid 38050041)
167. Hingorani SR, Wang L, Multani AS, et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 2005; 7: 469-83. (Pubitemid 40719130)
168. Olive KP, Jacobetz MA, Davidson CJ, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009; 324: 1457-61.
169. Grippo PJ, Nowlin PS, Demeure MJ, Longnecker DS, Sandgren EP. Preinvasive pancreatic neoplasia of ductal phenotype induced by acinar cell targeting of mutant Kras in transgenic mice. Cancer Res 2003; 63:2016-9. (Pubitemid 36538599)
170. Tuveson DA, Zhu L, Gopinathan A, et al. Mist1-KrasG12D knock-in mice develop mixed differentiation metastatic exocrine pancreatic carcinoma and hepatocellular carcinoma. Cancer Res 2006; 66: 242-7. (Pubitemid 43166030)
171. Izeradjene K, Combs C, Best M, et al. Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas. Cancer Cell 2007; 11: 229-43. (Pubitemid 46349845)
172. Grippo PJ, TuvesonDA. Deploying mouse models of pancreatic cancer for chemoprevention studies. Cancer Prev Res (Phila) 2010; 3: 1382-7.
173. International Cancer Genome Consortium et al. International network of cancer genome projects. Nature 2010; 464: 993-8.
174. Chang DK, Merrett ND, Biankin AV;. NSW Pancreatic Cancer Network. Improving outcomes for operable pancreatic cancer: is access to safer surgery the problem? J Gastroenterol Hepatol 2008; 23: 1036-45. (Pubitemid 352019387)